The following studies were recently activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.
Click the study links below to learn details regarding the studies on clinicaltrials.gov. For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.
Protocol Title: HCRN-LUN21-497: A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
PI: Frank Weinberg, MD, PhD, part of the Cancer Center’s Translational Oncology Research Program
Sponsor Investigator: Jeffrey Clarke, MD, Hoosier Cancer Research Network
Protocol Title: EA3163: Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-operative Radiation Versus Surgery and Post-operative Radiation for Organ Preservation of T3 and T4a (and selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
PI: Lawrence Feldman, MD, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: National Cancer Institute
Protocol Title: 8951-CL-5201: A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
PI: Shikha Jain, MD, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: Astellas Pharma Global
Protocol Title: AB-205-301: A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
PI: Chukwuemeka Uzoka, MD, part of the Cancer Center’s Cancer Biology Research Program
Sponsor: Angiocrene Bioesciences
PI: Chukwuemeka Uzoka, MD, part of the Cancer Center’s Cancer Biology Research Program
Sponsor: Janssen Pharmaceutical Inc.
PI: Chukwuemeka Uzoka, MD, part of the Cancer Center’s Cancer Biology Research Program
Sponsor: Beigene Ltd
Protocol Title: ACR-368-201: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
PI: Shannon MacLaughlan, MD, MS, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: Acrivon Therapeutics Inc
Protocol Title: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator’s Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
PI: Shannon MacLaughlan, MD, MS, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: Alliance
Protocol Title: INCB54828-209: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
PI: Ahmad Daher, MD, PhD, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: Incyte Corporation
